Apellis Pharmaceuticals Inc (APLS)
27.75
+0.26
(+0.95%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
-0.02
(-0.07%)
After-Hours: 20:00
Apellis Pharmaceuticals Total Liabilities (Quarterly): 664.74M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 664.74M |
| June 30, 2024 | 640.16M |
| March 31, 2024 | 565.25M |
| December 31, 2023 | 594.21M |
| September 30, 2023 | 585.94M |
| June 30, 2023 | 570.18M |
| March 31, 2023 | 566.75M |
| December 31, 2022 | 590.34M |
| September 30, 2022 | 565.48M |
| June 30, 2022 | 668.08M |
| March 31, 2022 | 683.62M |
| December 31, 2021 | 683.10M |
| September 30, 2021 | 583.01M |
| June 30, 2021 | 841.40M |
| March 31, 2021 | 758.47M |
| December 31, 2020 | 756.01M |
| September 30, 2020 | 662.49M |
| June 30, 2020 | 638.04M |
| Date | Value |
|---|---|
| March 31, 2020 | 429.94M |
| December 31, 2019 | 355.02M |
| September 30, 2019 | 326.80M |
| June 30, 2019 | 157.62M |
| March 31, 2019 | 93.60M |
| December 31, 2018 | 42.56M |
| September 30, 2018 | 43.19M |
| June 30, 2018 | 37.27M |
| March 31, 2018 | 34.16M |
| December 31, 2017 | 33.19M |
| September 30, 2017 | 6.938M |
| June 30, 2017 | 32.69M |
| December 31, 2016 | 3.639M |
| December 31, 2015 | 3.200M |
| September 30, 2015 | 2.656M |
| June 30, 2015 | 1.271M |
| December 31, 2014 | 1.082M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
355.02M
Minimum
Dec 2019
841.40M
Maximum
Jun 2021
620.11M
Average
616.13M
Median
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Ionis Pharmaceuticals Inc | 2.419B |
| EyePoint Pharmaceuticals Inc | 82.18M |
| Cassava Sciences Inc | 57.11M |
| Macrogenics Inc | 144.43M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 901.87M |
| Shareholders Equity (Quarterly) | 237.12M |
| Debt to Equity Ratio | 1.907 |
| Current Ratio | 4.36 |
| Net Debt Paydown Yield | -2.04% |